Cargando…
Duration of Protection against Malaria and Anaemia Provided by Intermittent Preventive Treatment in Infants in Navrongo, Ghana
BACKGROUND: Intermittent preventive treatment for malaria in Infants (IPTi) has been shown to give effective and safe protection against malaria. It has been suggested that IPTi might have long-lasting beneficial effects but, in most settings, the protection provided by IPTi appears to be short-live...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375060/ https://www.ncbi.nlm.nih.gov/pubmed/18493597 http://dx.doi.org/10.1371/journal.pone.0002227 |
_version_ | 1782154568067448832 |
---|---|
author | Cairns, Matthew Carneiro, Ilona Milligan, Paul Owusu-Agyei, Seth Awine, Timothy Gosling, Roly Greenwood, Brian Chandramohan, Daniel |
author_facet | Cairns, Matthew Carneiro, Ilona Milligan, Paul Owusu-Agyei, Seth Awine, Timothy Gosling, Roly Greenwood, Brian Chandramohan, Daniel |
author_sort | Cairns, Matthew |
collection | PubMed |
description | BACKGROUND: Intermittent preventive treatment for malaria in Infants (IPTi) has been shown to give effective and safe protection against malaria. It has been suggested that IPTi might have long-lasting beneficial effects but, in most settings, the protection provided by IPTi appears to be short-lived. Knowledge of the duration of protection given by IPTi would help interpret the results of existing trials and suggest optimal delivery schedules for IPTi. This study investigated how the protective efficacy of IPTi against malaria and anaemia changes over time. METHODS AND FINDINGS: A secondary analysis of data from a cluster-randomised, placebo-controlled trial of IPTi using sulfadoxine-pyrimethamine (SP) in Ghana was conducted. In this trial IPTi was given to 2485 infants at 3, 4, 9 and 12 months of age; children remained in follow-up until two years of age. Poisson regression with a random effect to adjust for the cluster-randomised design was used to determine protective efficacy of IPTi against clinical malaria and anaemia in defined time strata following administration of IPTi. Analysis of first-or-only clinical malaria episode following the individual IPTi doses showed that some protection against malaria lasted between 4 to 6 weeks. A similar pattern was seen when the incidence of all malaria episodes up to 2 years of age was analysed in relation to the most recent IPT, by pooling the incidence of malaria after the individual IPTi doses. Protective efficacy within four weeks of IPTi was 75.2% (95% CI: 66–82) against malaria, 78.9% (95% CI: 69–86) against high parasite density malaria, and 93.8% (95% CI: 73–99) against anaemia. Protection against these outcomes was short-lived, with evidence of any effect lasting for only 6, 6 and 4 weeks respectively. Protection in children who were parasitaemic when receiving IPTi appeared to be of shorter duration than in uninfected children. There was no evidence of any benefit of IPTi after the immediate period following the IPTi doses. CONCLUSIONS: Intermittent preventive treatment provides considerable protection against malaria and anaemia for short periods, even in an area of intense seasonal transmission. Due to the relatively short duration of protection provided by each dose of IPTi, this treatment will be of most benefit when delivered at the time of peak malaria incidence. |
format | Text |
id | pubmed-2375060 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-23750602008-05-21 Duration of Protection against Malaria and Anaemia Provided by Intermittent Preventive Treatment in Infants in Navrongo, Ghana Cairns, Matthew Carneiro, Ilona Milligan, Paul Owusu-Agyei, Seth Awine, Timothy Gosling, Roly Greenwood, Brian Chandramohan, Daniel PLoS One Research Article BACKGROUND: Intermittent preventive treatment for malaria in Infants (IPTi) has been shown to give effective and safe protection against malaria. It has been suggested that IPTi might have long-lasting beneficial effects but, in most settings, the protection provided by IPTi appears to be short-lived. Knowledge of the duration of protection given by IPTi would help interpret the results of existing trials and suggest optimal delivery schedules for IPTi. This study investigated how the protective efficacy of IPTi against malaria and anaemia changes over time. METHODS AND FINDINGS: A secondary analysis of data from a cluster-randomised, placebo-controlled trial of IPTi using sulfadoxine-pyrimethamine (SP) in Ghana was conducted. In this trial IPTi was given to 2485 infants at 3, 4, 9 and 12 months of age; children remained in follow-up until two years of age. Poisson regression with a random effect to adjust for the cluster-randomised design was used to determine protective efficacy of IPTi against clinical malaria and anaemia in defined time strata following administration of IPTi. Analysis of first-or-only clinical malaria episode following the individual IPTi doses showed that some protection against malaria lasted between 4 to 6 weeks. A similar pattern was seen when the incidence of all malaria episodes up to 2 years of age was analysed in relation to the most recent IPT, by pooling the incidence of malaria after the individual IPTi doses. Protective efficacy within four weeks of IPTi was 75.2% (95% CI: 66–82) against malaria, 78.9% (95% CI: 69–86) against high parasite density malaria, and 93.8% (95% CI: 73–99) against anaemia. Protection against these outcomes was short-lived, with evidence of any effect lasting for only 6, 6 and 4 weeks respectively. Protection in children who were parasitaemic when receiving IPTi appeared to be of shorter duration than in uninfected children. There was no evidence of any benefit of IPTi after the immediate period following the IPTi doses. CONCLUSIONS: Intermittent preventive treatment provides considerable protection against malaria and anaemia for short periods, even in an area of intense seasonal transmission. Due to the relatively short duration of protection provided by each dose of IPTi, this treatment will be of most benefit when delivered at the time of peak malaria incidence. Public Library of Science 2008-05-21 /pmc/articles/PMC2375060/ /pubmed/18493597 http://dx.doi.org/10.1371/journal.pone.0002227 Text en Cairns et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Cairns, Matthew Carneiro, Ilona Milligan, Paul Owusu-Agyei, Seth Awine, Timothy Gosling, Roly Greenwood, Brian Chandramohan, Daniel Duration of Protection against Malaria and Anaemia Provided by Intermittent Preventive Treatment in Infants in Navrongo, Ghana |
title | Duration of Protection against Malaria and Anaemia Provided by Intermittent Preventive Treatment in Infants in Navrongo, Ghana |
title_full | Duration of Protection against Malaria and Anaemia Provided by Intermittent Preventive Treatment in Infants in Navrongo, Ghana |
title_fullStr | Duration of Protection against Malaria and Anaemia Provided by Intermittent Preventive Treatment in Infants in Navrongo, Ghana |
title_full_unstemmed | Duration of Protection against Malaria and Anaemia Provided by Intermittent Preventive Treatment in Infants in Navrongo, Ghana |
title_short | Duration of Protection against Malaria and Anaemia Provided by Intermittent Preventive Treatment in Infants in Navrongo, Ghana |
title_sort | duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in navrongo, ghana |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375060/ https://www.ncbi.nlm.nih.gov/pubmed/18493597 http://dx.doi.org/10.1371/journal.pone.0002227 |
work_keys_str_mv | AT cairnsmatthew durationofprotectionagainstmalariaandanaemiaprovidedbyintermittentpreventivetreatmentininfantsinnavrongoghana AT carneiroilona durationofprotectionagainstmalariaandanaemiaprovidedbyintermittentpreventivetreatmentininfantsinnavrongoghana AT milliganpaul durationofprotectionagainstmalariaandanaemiaprovidedbyintermittentpreventivetreatmentininfantsinnavrongoghana AT owusuagyeiseth durationofprotectionagainstmalariaandanaemiaprovidedbyintermittentpreventivetreatmentininfantsinnavrongoghana AT awinetimothy durationofprotectionagainstmalariaandanaemiaprovidedbyintermittentpreventivetreatmentininfantsinnavrongoghana AT goslingroly durationofprotectionagainstmalariaandanaemiaprovidedbyintermittentpreventivetreatmentininfantsinnavrongoghana AT greenwoodbrian durationofprotectionagainstmalariaandanaemiaprovidedbyintermittentpreventivetreatmentininfantsinnavrongoghana AT chandramohandaniel durationofprotectionagainstmalariaandanaemiaprovidedbyintermittentpreventivetreatmentininfantsinnavrongoghana |